Trial Profile
OASIS: Open-label, Dose-escalation, Phase 1/2a Study of the Safety and Tolerability of Suprachoroidally Administered CLS-AX Following Intravitreal Anti-VEGF Therapy in Subjects With Neovascular Age-related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Nov 2023
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; Aflibercept
- Indications Choroidal neovascularisation; Wet age-related macular degeneration
- Focus Adverse reactions
- Acronyms OASIS
- Sponsors Clearside Biomedical
- 13 Nov 2023 According to a Clearside Biomedical media release, data from this study were presented at AAO.
- 16 Oct 2023 According to a Clearside Biomedical media release, positive OASIS and extension study data from the Phase 1/2a OASIS clinical trial were presented at The Retina Society 56th Annual Scientific Meeting.
- 31 Jul 2023 According to a Clearside Biomedical Media Release, safety and tolerability data were presented at the American Society of Retina Specialists (ASRS) 41st Annual Scientific Meeting.